338 related articles for article (PubMed ID: 32591986)
21. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
[TBL] [Abstract][Full Text] [Related]
22. Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.
Tan X; Camacho TF; LeBaron VT; Blackhall LJ; Balkrishnan R
Breast Cancer Res Treat; 2017 Sep; 165(2):455-465. PubMed ID: 28639031
[TBL] [Abstract][Full Text] [Related]
23. Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients.
Rosso R; D'Alonzo M; Bounous VE; Actis S; Cipullo I; Salerno E; Biglia N
Curr Oncol; 2023 Jan; 30(2):1461-1472. PubMed ID: 36826073
[TBL] [Abstract][Full Text] [Related]
24. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
Meneveau MO; Keim-Malpass J; Camacho TF; Anderson RT; Showalter SL
Breast Cancer Res Treat; 2020 Dec; 184(3):805-816. PubMed ID: 32920742
[TBL] [Abstract][Full Text] [Related]
25. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
Farias AJ; Wu WH; Du XL
BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
[TBL] [Abstract][Full Text] [Related]
26. Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer.
Sheppard VB; Dash C; Nomura S; Sutton AL; Franco RL; Lucas A; Ross M; Adams-Campbell L
Cancer; 2020 Sep; 126(17):4059-4066. PubMed ID: 32614992
[TBL] [Abstract][Full Text] [Related]
27. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
[TBL] [Abstract][Full Text] [Related]
28. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
[TBL] [Abstract][Full Text] [Related]
29. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
Lambert LK; Balneaves LG; Howard AF; Gotay CC
Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
[TBL] [Abstract][Full Text] [Related]
30. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
[TBL] [Abstract][Full Text] [Related]
31. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
32. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA
Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753
[TBL] [Abstract][Full Text] [Related]
33. Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors.
Uslu Y; Kocatepe V; Sezgin DS; Uras C
Support Care Cancer; 2023 Apr; 31(5):285. PubMed ID: 37079089
[TBL] [Abstract][Full Text] [Related]
34. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?
Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV
J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760
[TBL] [Abstract][Full Text] [Related]
35. Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis.
Mausbach BT; Schwab RB; Irwin SA
Breast Cancer Res Treat; 2015 Jul; 152(2):239-46. PubMed ID: 26077640
[TBL] [Abstract][Full Text] [Related]
36. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.
Font R; Espinas JA; Barnadas A; Izquierdo A; Galceran J; Saladie F; Marcos-Gragera R; Torrent A; Manchon-Walsh P; Borras JM
Breast Cancer Res Treat; 2019 Jun; 175(3):733-740. PubMed ID: 30887164
[TBL] [Abstract][Full Text] [Related]
37. Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records.
Thorén L; Margolin S; Eliasson E; Bergh J; Lindh JD
Breast Cancer Res Treat; 2023 Apr; 198(3):499-508. PubMed ID: 36856936
[TBL] [Abstract][Full Text] [Related]
38. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy.
Akin Telli T; Ozturk MA; Alan O; Hasanov R; Kostek O; Arikan R; Basoglu T; Kaya S; Ercelep O; Akgul Babacan N; Dane F; Yumuk PF
Future Oncol; 2022 Jul; 18(22):2425-2439. PubMed ID: 35695547
[TBL] [Abstract][Full Text] [Related]
39. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
40. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer.
Nekhlyudov L; Li L; Ross-Degnan D; Wagner AK
Breast Cancer Res Treat; 2011 Nov; 130(2):681-9. PubMed ID: 21842245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]